Phase 2 Study of MM-093 to Treat Patients With Uveitis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the tolerability, pharmacokinetics,
pharmacodynamics, and biologic activity of MM-093 in patients with moderate to severe
uveitis.